CSIMarket Company Name, Ticker, Competitors, else..
 
Sensei Biotherapeutics Inc   (NASDAQ: SNSE)
Other Ticker:  
 
 
Price: $0.4600 $0.00 0.789%
Day's High: $0.48 Week Perf: -13.91 %
Day's Low: $ 0.46 30 Day Perf: -6.14 %
Volume (M): 69 52 Wk High: $ 1.94
Volume (M$): $ 32 52 Wk Avg: $0.76
Open: $0.47 52 Wk Low: $0.38



 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 25
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Sensei Biotherapeutics Inc
Sensei Biotherapeutics Inc is a biopharmaceutical company that focuses on developing precision immuno-oncology therapies. The company harnesses the power of the immune system to target specific tumor antigens, with the goal of improving outcomes for cancer patients. Sensei Biotherapeutics utilizes its proprietary ImmunoPhage platform to design and develop personalized vaccines and cell therapies. The company's approach involves engineering bacteriophage-based delivery vehicles to deliver tumor antigens directly to immune cells, promoting a targeted immune response against cancer cells. Sensei Biotherapeutics aims to advance the field of immuno-oncology by leveraging its innovative platform and expertise in tumor-specific immunology.


   Company Address: 1405 Research Blvd Rockville 20850 MD
   Company Phone Number: 243-8000   Stock Exchange / Ticker: NASDAQ SNSE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT        12.12% 
BPMC   -0.19%    
NRIX   -0.19%    
RYTM   -3.05%    
SUPN   -3.05%    
YMAB   -3.05%    
• View Complete Report
   



Clinical Study

Sensei Biotherapeutics, a leading biotechnology company focused on the development of immunotherapies, has recently presented encouraging clinical data from its Phase 1 dose escalation study of SNS-101. The study demonstrated initial signs of promising clinical activity, marking a significant milestone in the quest for effective cancer treatments.SNS-101, a novel ca...

Published Thu, May 23 2024 9:10 PM UTC

NEWS HEADLINE: Sensei Biotherapeutics' SNS-101 Shows Promising Clinical Activity in Phase 1 Dose Escalation StudySensei Biotherapeutics, a leading biotechnology company focused on the development of immunotherapies, has recently presented encouraging clinical data from its Phase 1 dose escalation study of SNS-101. The study demonstrated initial signs of promising clinical ac...
Product Service News

Exploring New Horizons: Sensei Biotherapeutics Unravels Topline Clinical Data at the 2024 ASCO Annual Meeting

Published Wed, Apr 24 2024 8:05 PM UTC

In the rapidly evolving sphere of immuno-oncology, Sensei Biotherapeutics, Inc., a clinical-stage company, has emerged as a significant player. Raising the bar further, Sensei recently announced that the company is set to present the topline clinical data from its innovative Phase 1/2 trial study of SNS-101, a potential breakthrough in cancer therapeutics. This highly antici...
Product Service News

Elucidating the Selective Targeting Mechanism of SNS-101 on the Active Form of VISTA within the Tumor Microenvironment

Published Thu, Apr 4 2024 8:05 PM UTC

Sensei Biotherapeutics, Inc., an immuno-oncology firm embarked on discovering and evolving next-generation therapeutics for cancer, has announced the debut of a research paper in the globally recognized Nature Communications. This noteworthy study elucidates the mechanism of action (MoA) of SNS-101, an inventive drug developed by the company, demonstrating its selective targ...
Sensei Biotherapeutics Inc

Sensei Biotherapeutics Inc. showcases remarkable progress in financial performance, reports improved operating shortfall of -$7.737 million in Q3 2023

Sensei Biotherapeutics Inc, a major player in the pharmaceutical preparations industry, is making significant strides in their financial performance as evidenced by their recent earnings report for the third quarter of 2023. Despite reporting an operating shortfall of -$7.737 million, the company's efficiency has improved when compared to the same period last year when the operating shortfall was -$13.941 million.
This improvement in operating shortfall signifies progress for Sensei Biotherapeutics Inc, as they have successfully reduced their deficit from the previous year. The third quarter of 2022 recorded a deficit of -$13.416 million, whereas the recent third quarter of 2023 reported a lower deficit of -$7.124 million. This reduction in deficit is a crucial development for the company, signaling that they are moving in a positive direction financially.
Sensei Biotherapeutics Inc

Sensei Biotherapeutics Outperforms Previous Year's Q2 Results, Fuelling Investor Optimism

Sensei Biotherapeutics Inc, a leading player in the Major Pharmaceutical Preparations industry, recently released its second quarter performance report for 2023. The report came with an operating shortfall of $-10.177 million, which is slightly better than the shortfall of $-10.712 million reported for the same period last year. This positive development has sparked optimism among numerous investors who have been closely following the company's progress.
Despite not specifying its top-line figures for the April to June 30, 2023 financial reporting period, Sensei Biotherapeutics Inc has managed to significantly reduce losses to $-9.386 million. This enhanced performance demonstrates the company's commitment to efficient management and showcases its potential for future growth.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com